These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24780466)

  • 1. Dimethylarginines ADMA and SDMA: the real water-soluble small toxins?
    Schepers E; Speer T; Bode-Böger SM; Fliser D; Kielstein JT
    Semin Nephrol; 2014 Mar; 34(2):97-105. PubMed ID: 24780466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asymmetric dimethylarginine and symmetric dimethylarginine: axis of evil or useful alliance?
    Kielstein JT; Fliser D; Veldink H
    Semin Dial; 2009; 22(4):346-50. PubMed ID: 19708979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxic Dimethylarginines: Asymmetric  Dimethylarginine (ADMA) and Symmetric  Dimethylarginine (SDMA).
    Tain YL; Hsu CN
    Toxins (Basel); 2017 Mar; 9(3):. PubMed ID: 28272322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asymmetric (ADMA) and Symmetric (SDMA) Dimethylarginines in Chronic Kidney Disease: A Clinical Approach.
    Oliva-Damaso E; Oliva-Damaso N; Rodriguez-Esparragon F; Payan J; Baamonde-Laborda E; Gonzalez-Cabrera F; Santana-Estupiñan R; Rodriguez-Perez JC
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.
    Emrich IE; Zawada AM; Martens-Lobenhoffer J; Fliser D; Wagenpfeil S; Heine GH; Bode-Böger SM
    Clin Res Cardiol; 2018 Mar; 107(3):201-213. PubMed ID: 29101459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The past, presence and future of ADMA in nephrology.
    Kielstein JT; Fliser D
    Nephrol Ther; 2007 Apr; 3(2):47-54. PubMed ID: 17452300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?
    Kielstein JT; Zoccali C
    Am J Kidney Dis; 2005 Aug; 46(2):186-202. PubMed ID: 16112037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arginine, dimethylated arginine and homoarginine in relation to cardiovascular risk in patients with moderate chronic kidney disease.
    Hov GG; Aasarød KI; Sagen E; Åsberg A
    Clin Biochem; 2015 Jul; 48(10-11):646-51. PubMed ID: 25828044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.
    Betz B; Möller-Ehrlich K; Kress T; Kniepert J; Schwedhelm E; Böger RH; Wanner C; Sauvant C; Schneider R
    Transl Res; 2013 Aug; 162(2):67-76. PubMed ID: 23707198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous quantitative determination of N(G),N(G)-dimethyl-L-arginine or asymmetric dimethylarginine and related pathway's metabolites in biological fluids by ultrahigh-performance liquid chromatography/electrospray ionization-tandem mass spectrometry.
    Di Gangi IM; Chiandetti L; Gucciardi A; Moret V; Naturale M; Giordano G
    Anal Chim Acta; 2010 Sep; 677(2):140-8. PubMed ID: 20837180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease.
    Kielstein JT; Zoccali C
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):609-15. PubMed ID: 18941355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
    Busch M; Fleck C; Wolf G; Stein G
    Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of asymmetric dimethylarginine and endothelial dysfunction.
    Böger RH
    Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
    Böger RH; Bode-Böger SM
    Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPLC determination of plasma dimethylarginines: method validation and preliminary clinical application.
    Ivanova M; Artusi C; Boffa GM; Zaninotto M; Plebani M
    Clin Chim Acta; 2010 Nov; 411(21-22):1632-6. PubMed ID: 20542018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [ADMA (asymmetric dimethylarginine)--the inhibitor of nitric oxide (NO) synthesis: a new marker for vascular pathology].
    Sela BA
    Harefuah; 2005 Sep; 144(9):655-9, 675, 674. PubMed ID: 16218539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease.
    Alpoim PN; Sousa LP; Mota AP; Rios DR; Dusse LM
    Clin Chim Acta; 2015 Feb; 440():36-9. PubMed ID: 25444745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of asymmetrical dimethylarginine in the progression of renal disease.
    Raptis V; Kapoulas S; Grekas D
    Nephrology (Carlton); 2013 Jan; 18(1):11-21. PubMed ID: 23016674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
    Siroká R; Cibulka R; Rajdl D; Racek J
    Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study.
    Aucella F; Maas R; Vigilante M; Tripepi G; Schwedhelm E; Margaglione M; Gesualdo L; Boeger R; Zoccali C
    Atherosclerosis; 2009 Dec; 207(2):541-5. PubMed ID: 19501358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.